ORIC Pharmaceuticals, Inc.
ORIC
$5.78
$0.254.52%
| Weiss Ratings | ORIC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | ORIC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ORIC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.48 | |||
| Price History | ORIC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -21.57% | |||
| 30-Day Total Return | -27.20% | |||
| 60-Day Total Return | -32.40% | |||
| 90-Day Total Return | -34.98% | |||
| Year to Date Total Return | -30.02% | |||
| 1-Year Total Return | -52.51% | |||
| 2-Year Total Return | -1.53% | |||
| 3-Year Total Return | -18.25% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -62.30% | |||
| 52-Week Low % Change | 5.33% | |||
| Price | ORIC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $14.67 | |||
| 52-Week Low Price | $5.25 | |||
| 52-Week Low Price (Date) | Apr 01, 2025 | |||
| 52-Week High Price (Date) | Feb 10, 2025 | |||
| Valuation | ORIC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 392.78M | |||
| Enterprise Value | 146.18M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.83 | |||
| Earnings Per Share Growth | -7.15% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 1.62 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $5.78 | |||
| Enterprise Value/EBITDA (TTM) | -1.03 | |||
| Enterprise Value/EBIT | -1.02 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | ORIC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 70.65M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ORIC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 650 388 5600 | |||
| Address | 240 East Grand Avenue South San Francisco, CA 94080 | |||
| Website | www.oricpharma.com | |||
| Country | United States | |||
| Year Founded | 2014 | |||
| Profitability | ORIC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | ORIC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -33.95% | |||
| Return on Equity | -- | |||
| Income Statement | ORIC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -141.79M | |||
| EBIT (TTM) | -142.90M | |||
| Net Income (TTM) | -127.85M | |||
| Net Income Avl. to Common (TTM) | -127.85M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -28.16% | |||
| EPS Diluted (TTM) | -1.83 | |||
| EPS Diluted Growth (Q YOY) | -4.24% | |||
| Balance Sheet | ORIC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 255.96M | |||
| Cash Per Share (Q) | $3.62 | |||
| Total Current Assets (Q) | 262.25M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 243.12M | |||
| Current Ratio (Q) | 10.555 | |||
| Book Value Per Share (Q) | $3.42 | |||
| Total Assets (Q) | 274.14M | |||
| Total Current Liabilities (Q) | 24.85M | |||
| Total Debt (Q) | 9.36M | |||
| Total Liabilities (Q) | 31.02M | |||
| Total Common Equity (Q) | 243.12M | |||
| Cash Flow | ORIC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 22.14M | |||
| Cash from Financing (TTM) | 126.55M | |||
| Net Change in Cash (TTM) | 36.02M | |||
| Levered Free Cash Flow (TTM) | -67.10M | |||
| Cash from Operations (TTM) | -112.66M | |||
